Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rit...
Saved in:
Main Authors: | Giulia Motta, Michele Cea, Eva Moran, Federico Carbone, Valeria Augusti, Franco Patrone, Alessio Nencioni |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2010/428253 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma
by: Sun Hee Chang, et al.
Published: (2015-01-01) -
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
by: Caron A. Jacobson, et al.
Published: (2012-01-01) -
NonHodgkin's Lymphoma with Peritoneal Localization
by: E. Curakova, et al.
Published: (2014-01-01) -
Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2024-10-01) -
Role of Monoclonal Antibodies in the Treatment of Asthma
by: Paul M O’Byrne
Published: (2013-01-01)